HSBC Holdings
ACAD icon

HSBC Holdings’s Acadia Pharmaceuticals ACAD Stock Holding History

HSBC Holdings’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$984K Sell
38,862
-5,146
-12% -$113K ﹤0.01% 1952
2026
Q1 		$977K Buy
44,008
+17,722
+67% +$424K ﹤0.01% 1872
2025
Q4 		$703K Sell
26,286
-4,505
-15% -$108K ﹤0.01% 2142
2025
Q3 		$652K Sell
30,791
-7,840
-20% -$185K ﹤0.01% 1972
2025
Q2 		$835K Sell
38,631
-24,686
-39% -$459K ﹤0.01% 1891
2025
Q1 		$1.04M Sell
63,317
-5,704
-8% -$104K ﹤0.01% 1737
2024
Q4 		$1.27M Buy
69,021
+4,025
+6% +$65K ﹤0.01% 1677
2024
Q3 		$1.01M Buy
64,996
+51,448
+380% +$858K ﹤0.01% 1694
2024
Q2 		$220K Buy
13,548
+407
+3% +$6.57K ﹤0.01% 2491
2024
Q1 		$243K Buy
+13,141
New +$326K ﹤0.01% 2568
2022
Q3 		– Sell
-10,566
Closed -$149K – 2895
2022
Q2 		$149K Sell
10,566
-2,275
-18% -$42.5K ﹤0.01% 2954
2022
Q1 		$314K Buy
+12,841
New +$311K ﹤0.01% 2721
2021
Q3 		– Sell
-27,563
Closed -$681K – 2961
2021
Q2 		$681K Buy
27,563
+6,343
+30% +$143K ﹤0.01% 1980
2021
Q1 		$545K Buy
21,220
+14,768
+229% +$650K ﹤0.01% 1925
2020
Q4 		$345K Sell
6,452
-11,038
-63% -$548K ﹤0.01% 2476
2020
Q3 		$720K Sell
17,490
-3,675
-17% -$159K ﹤0.01% 1722
2020
Q2 		$1.03M Buy
21,165
+15,728
+289% +$755K ﹤0.01% 1434
2020
Q1 		$230K Sell
5,437
-12,492
-70% -$515K ﹤0.01% 2206
2019
Q4 		$762K Buy
17,929
+9,970
+125% +$434K ﹤0.01% 1987
2019
Q3 		$286K Buy
+7,959
New +$241K ﹤0.01% 2651
2019
Q2 		– Sell
-7,896
Closed -$212K – 2684
2019
Q1 		$212K Buy
+7,896
New +$184K ﹤0.01% 2528
2018
Q1 		– Sell
-13,557
Closed -$408K – 2532
2017
Q4 		$408K Buy
+13,557
New +$434K ﹤0.01% 1577

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HSBC Holdings's ACAD Position: Q2 2026 in Review

HSBC Holdings reduced its Acadia Pharmaceuticals (ACAD) stake by 12% in Q2 2026, selling an estimated $113K and leaving 38,862 shares worth $984K. The position accounts for ﹤0.01% of the portfolio, ranked #1952.

HSBC Holdings first reported a position in ACAD in Q4 2017 and has held it in 22 quarters since. The position peaked at $1.27M in Q4 2024. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • HSBC Holdings held 38,862 shares of Acadia Pharmaceuticals worth $984K as of Q2 2026.
  • HSBC Holdings sold 5,146 Acadia Pharmaceuticals shares in Q2 2026, an estimated $113K.
  • Acadia Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #1952 holding.
  • HSBC Holdings first reported a position in Acadia Pharmaceuticals in Q4 2017 and has held it in 22 quarters since.
  • HSBC Holdings's Acadia Pharmaceuticals position peaked at $1.27M in Q4 2024.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.